The global market for non-melanoma skin cancer treatment is expected to reach \$8.86 billion. This growth is largely driven by a rising number of skin cancer cases worldwide, a trend linked in part to increasing global temperatures that raise UV exposure and the risk of developing skin cancer. As more people are affected, demand for effective diagnosis and treatment options continues to rise.
Radiation therapy remains the most common treatment for non-melanoma skin cancer. Recent advances have focused on making radiation equipment more patient-friendly and accessible. Portable and compact machines now allow patients greater flexibility during treatment, reducing the need to stay confined to one location and improving overall comfort. These improvements have helped boost the use of radiation therapy in skin cancer care.
North America dominates the non-melanoma skin cancer market, accounting for an estimated 58% share with a value of nearly \$2.94 billion in 2024. Although its share is expected to decrease slightly over the next decade, the region will remain a significant player, with its market value projected to reach \$3.93 billion by 2034. Meanwhile, East Asia is emerging as a fast-growing market. Though it currently holds less than 1% of the market, valued at \$40 million in 2024, the region is expected to expand at a rate of 5.6% annually and nearly double in size by 2034. This growth reflects improved healthcare infrastructure, increased awareness, and a rising demand for cancer treatment in the area.
Radiation therapy is set to hold nearly 89% of the treatment market in 2024, making it the dominant method for managing non-melanoma skin cancer. Photodynamic therapy, a less invasive alternative, is gaining popularity and expected to capture nearly 9% of the market. In terms of types of skin cancer, basal cell carcinoma remains the most common, accounting for about 76% of cases, while squamous cell carcinoma represents roughly 24%.
Key companies in the market, including Amgen, Regeneron, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Merck, Novartis, Eli Lilly, and Sun Pharmaceutical, are investing heavily in research and development to improve treatment effectiveness. Collaborations with academic and research institutions are increasing, supported by financial backing to speed up innovation. Public health campaigns aimed at raising awareness and encouraging early diagnosis are also helping to drive market growth.
Related Topics:
